Zymeworks (NASDAQ:ZYME) Stock Breaks Below Fifty Day Moving Average – What’s Next?

Zymeworks Inc. (NASDAQ:ZYME) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $27.39 and traded as low as $26.43. Zymeworks shares last traded at $26.47, with a volume of 1,331,913 shares trading hands.

Zymeworks News Roundup

Here’s some of the latest news about ZYME:

• Positive Sentiment: Citigroup raised its price target to $44 from $39 and maintained a Buy rating. Truist also forecast strong price appreciation, while TD Cowen lifted its target, adding to the positive analyst outlook. Truist Financial Forecasts Strong Price Appreciation for Zymeworks Zymeworks Stock Gets Price Target Boost from TD Cowen
• Positive Sentiment: Zymeworks recently reported better-than-expected earnings and reached a 52-week high, suggesting strong results had supported investor demand. Zymeworks Hits New 52-Week High After Better-Than-Expected Earnings
• Negative Sentiment: HC Wainwright cut estimates across several upcoming quarters and reduced its FY2026 EPS forecast to $1.19 from $1.51. Its FY2027 outlook shifted from expected earnings of $1.32 per share to a loss of $0.39 per share. These substantial revisions are a negative near-term signal, although the firm kept its Buy rating and $56 target. Zymeworks analyst and stock information

Analyst Ratings Changes

A number of equities analysts have recently commented on ZYME shares. Jefferies Financial Group reiterated a “buy” rating and set a $52.00 price target on shares of Zymeworks in a report on Friday, October 23rd. Deutsche Bank set a $32.00 price objective on Zymeworks in a report on Wednesday, August 26th. B. Riley Financial restated a “buy” rating and issued a $44.00 price objective (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. JPMorgan Chase & Co. raised their target price on Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Finally, Stifel Nicolaus set a $46.00 price target on Zymeworks in a research report on Friday, August 7th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.67.

Zymeworks Stock Performance

The company has a 50 day moving average price of $27.39 and a 200 day moving average price of $25.46. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 50.90 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.27 by $0.01. The firm had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The company’s quarterly revenue was up 828.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.26) earnings per share. Research analysts forecast that Zymeworks Inc. will post 1.31 EPS for the current year.

Insider Transactions at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the sale, the executive vice president owned 23,205 shares in the company, valued at $599,849.25. This represents a 37.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zymeworks

Institutional investors have recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its stake in Zymeworks by 759.9% in the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after buying an additional 537,837 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Zymeworks by 104.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after buying an additional 50,127 shares in the last quarter. Calamos Advisors LLC purchased a new position in shares of Zymeworks in the 3rd quarter worth approximately $1,232,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Zymeworks in the 3rd quarter worth approximately $96,000. Finally, ProShare Advisors LLC grew its holdings in shares of Zymeworks by 91.5% in the third quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock valued at $434,000 after acquiring an additional 7,833 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.